Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||uveal melanoma||not applicable||IDE196||Phase I||Actionable||In a Phase I trial, LXS196 demonstrated safety and preliminary efficacy, resulted in partial response in 9% (6/66) and stable disease in 68% (45/66) of patients with metastatic uveal melanoma (AACR Annual Meeting 2019, Abstract CT068).||detail...|
|PubMed Id||Reference Title||Details|
|A Phase I trial of LXS196, a novel PKC inhibitor for metastatic uveal melanoma||Full reference...|